Antiblastic Treatment and Haematological Malignancies during Pregnancy: A Crucial Decision

M. Michieli, F. A. Peccatori, A. Lleshi, L. Del Pup, D. Valente, M. Rupolo, U. Tirelli, M. Berretta

Research output: Contribution to journalArticlepeer-review


Antiblastic treatment of hematological malignancies during pregnancy poses a number of issues related to the curability of the maternal disease, the need of a prompt treatment and the potential toxicity of chemotherapy for the fetus. Here we report the results of a systematic literature search about the management of the most frequent hematological malignancies that may occur during pregnancy, focusing on specific issues related to gestational age at diagnosis, fetal toxicity and efficacy on the maternal side. The standard approach in non-pregnant women is illustrated as reference.

Original languageEnglish
Pages (from-to)21-32
Number of pages12
JournalInternational Journal of Immunopathology and Pharmacology
Publication statusPublished - Apr 1 2012


  • Cancer
  • Chemotherapy
  • Hematological malignancies
  • Pregnancy
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Antiblastic Treatment and Haematological Malignancies during Pregnancy: A Crucial Decision'. Together they form a unique fingerprint.

Cite this